Human cryptococcosis (torulosis) was first recognized as a clinical entity in 1914 by Versé.1 Previous reports by Busse and Buschke,2 Gilchrist,3 and Curtis4 at the end of the 19th century, however, indicate that they had actually described Cryptococcus infections in man but had not classified the yeast as Cryptococcus hominis (Torula histolytica). Since that time three monographs5 and innumerable articles have appeared in the world literature describing the characteristics of human infestations with this organism, and to date approximately 200 cases have been reported.
Although acute forms of the disease have been known, typically human Cryptococcus infections are of a chronic nature and most commonly implicate the central nervous system and lungs. Isolated instances of recovery have been cited,6 but death is the expected termination of the disease. No specific mode of therapy is known.
In spite of an increasing number of reports of
Cook AW. CRYPTOCOCCUS (TORULA) MENINGITIS: REPORT OF TWO CASES. JAMA. 1951;146(12):1105–1107. doi:10.1001/jama.1951.03670120015004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: